COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cogent Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$30.01+0.49 (+1.66%)
Close on Oct 19, 2026
- Market cap
- $5.13B
- P/E (TTM)
- –
- Dividend yield
- –
Cogent Biosciences, Inc. revenue by segment
By business segment
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | YoY |
|---|---|---|---|---|---|
| Late-stage Development [Member] | $120.06M | $120.86M | $85.48M | $61.27M | -0.7% |
| R&D Personnel Related [Member] | $64.04M | $47.05M | $38.21M | $26.42M | +36.1% |
| Stock-Based Compensation Expense [Member] | $46.08M | $39.74M | $30.62M | $18.37M | +16.0% |
| Other Operational Infrastructure and Advisory Support [Member] | $40.43M | $26.89M | $23.01M | $21.61M | +50.4% |
| Early-stage, Preclinical and Discovery Programs [Member] | $40.11M | $28.14M | $19.17M | $12.96M | +42.5% |
| Research and Development Software, Facilities and Other Strategic Support [Member] | $20.09M | $10.81M | $9.37M | $6.38M | +85.8% |
| Depreciation Expense [Member] | $2.56M | $2.45M | $2.26M | $842.00K | +4.7% |
By product or service
By region
From the segment and revenue-disaggregation notes of Cogent Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.